|Mr. John J. Sperzel III||Pres, CEO & Director||897.27k||N/A||1964|
|Mr. Anthony Pare||Chief Commercial Officer||513.25k||N/A||1963|
|Dr. Tyler E. Jacks||Co-Founder||N/A||N/A||1961|
|Mr. Lee Josephson||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. John M. Sprague CPA||Chief Financial Officer||N/A||N/A||1959|
|Mr. Michael Terrence Gibbs||VP & Gen. Counsel||N/A||N/A||1971|
|Ms. Kelley Morgan||Chief People Officer||N/A||N/A||N/A|
|Ms. Sandy J. Estrada Pharm.D.||VP of Medical Affairs||N/A||N/A||N/A|
|Dr. Joanne Spadoro||Consultant||N/A||N/A||1959|
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
T2 Biosystems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.